Task Force on Desensitization Preliminary Questionnaire –In which clinical situations have desensitization been performed –To which drugs? –Which protocol.

Slides:

Advertisements

Similar presentations

Managing CF patients with antibiotic hypersensitivity

Advertisements

The Impact of Climatic and Environmental Factors for Asthma ER Visits in NYC Cindy Law Mary Lee-Wong, MD.

A case series of ART-associated gynaecomastia reported to the National HIV & TB Healthcare Workers (HCW) hotline Christine Njuguna. Division of Clinical.

Drug Hypersensitivity Prevalence in the Adult Population Group 13 Medical Faculty of University of Porto Medical Faculty of University of Porto Introduction.

Drug Hypersensitivity Prevalence in the Adult Population Group 13 Faculty of Medicine of the University of Porto Faculty of Medicine of the University.

Drug Allergy Prevalence in the Adult Population Group 13 Faculty of Medicine of the University of Porto Faculty of Medicine of the University of Porto.

General Pharmacology.

Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.

A Patient with Recurring Infections Julia Wright, M.D. Clinical Associate Professor of Medicine Section of General Internal Medicine.

Documentation. Screening Questions 1. 1.Is your child sick today? 2. 2.Does your child have allergies to medications, food, or any vaccine? 3. 3.Has the.

Anti-IgE Use in Allergy

Outcome of a Prevention of mother to child transmission (PMTCT ) programme following Implementation of prophylaxis for HIV infected pregnant women in Barbados:

Hepatitis C Consultation Services (844) | 9AM-5PM ET, M-F nccc.ucsf.edu The Clinician Consultation Center (CCC) provides up-to-date expert clinical.

Immunotherapy for Allergic Rhinitis

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Recognition and First-Line Treatment of Anaphylaxis

Providing ARVs to children in resource limited settings

Infection Control in the ICU

Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: Treatment implications Michael H. Smolensky, PhDa, Alain Reinberg, MDb,

Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.

INTRODUCTION The oral route of drugs administration is the most important method of administering drugs for systemic effects.

Von Ta, MD, Andrew A. White, MD

Defining future risk in asthma Pt. II

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Approach to Perioperative Antibiotic Treatment in

The use of cotrimoxazole prophylaxis in the context of HIV infection

Katharine M. Woessner, MD, FAAAAI, Andrew A. White, MD, FAAAAI

The epidemiology of the atopic child

Justin R. Chen, MD, Scott A. Tarver, PharmD, Kristin S

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

11/23/2018 National University of Lesotho, Southern Africa

Improving the Effectiveness of Penicillin Allergy De-labeling

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Complementary and Alternative Medicine in Allergy-Immunology: More Information is Needed Leonard Bielory, MD The Journal of Allergy and Clinical Immunology:

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Biologics in patients with skin diseases

Laboratory animal allergy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Characteristics and Outcomes of HEDIS-Defined Asthma Patients with COPD Diagnostic Coding Robert S. Zeiger, MD, PhD, Michael Schatz, MD, MS, Qiaowu Li,

Desensitization to Chemotherapeutic Agents

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Badrul A. Chowdhury, MD, PhD

Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases Dhavalkumar D. Patel, MD, PhD, Christian Antoni,

MANAGEMENT OF PCP Dr. Akaninyene A. Otu, MBBCh, DTM&H, MPH, MRCP (UK), FWACP University of Calabar Teaching Hospital Calabar, Nigeria.

Katherine N. Cahill, MD, Jillian C. Bensko, Joshua A

Dr Immaculate Kariuki Consultant Paediatrician Nairobi, Kenya

Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review Amy S. Levin, MD, Iris M. Otani, MD, Timothy Lax, MD, Ephraim Hochberg, MD, Aleena.

The impact of allergic rhinitis on bronchial asthma

Improving the Effectiveness of Penicillin Allergy De-labeling

Dr Amy Stebbings The Chest and Internal Medicine Clinic, Singapore

Methodological cutoff of basophil activation test and basophil activation test diagnostic value Sten Dreborg, MD, PhD The Journal of Allergy and Clinical.

Controversies in Drug Allergy: Radiographic Contrast Media

Penicillin Skin Testing Is a Safe and Effective Tool for Evaluating Penicillin Allergy in the Pediatric Population Stephanie J. Fox, MD, Miguel A. Park,

Peter König, MD, PhD Journal of Allergy and Clinical Immunology

Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center study Jeremy Waldram, MD, Kristen Walters,

News & Notes Journal of Allergy and Clinical Immunology

Biosimilars and drug development in allergic and immunologic diseases

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Effect of β-adrenergic agonists on mucociliary clearance

Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell–mediated hypersensitivity to penicillins Antonino Romano,

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

News & Notes Journal of Allergy and Clinical Immunology

Von Ta, MD, Andrew A. White, MD

Xiu-Min Li, MD, LaVerne Brown, PhD

Fig. 3. Typical protocol for oral and sublingual immunotherapy

News & Notes Journal of Allergy and Clinical Immunology

Associations between the ‘% of patients that ever used a bDMARD’ and the ‘composite score clinical criteria’, ‘composite score access to medication’ and.

Desloratadine: A new, nonsedating, oral antihistamine

Presentation transcript:

Task Force on Desensitization Preliminary Questionnaire –In which clinical situations have desensitization been performed –To which drugs? –Which protocol (reference/s)? –Total number of patients in each drug group –Total number of desensitizations (for each drug group) –Outcomes / how they have been measured? –Simultaneous in vitro analysis have bee done?

Task Force on Desensitization Gul Karakaya Dpt Chest Diseases – Adult Allergy Unit – Turkey ASA/ 22 patients/ modified protocol (?) Outcomes: Clinical scales, FEV1, QoLQ Gulfem Celik Dpt Allergy Ankara Medical School - Turkey Atb (quinolones – protocol ?) Going to start on ASA Kvedariene Violeta (Lithuania)No (planning) Joanna Makowska (Poland)No (planning) Antonino Romano Unità di Allergologia, Complesso Integrato Columbus - Italy No (only in Polliclinico Gemely – Beta- lactams in CF – protocol ?) Andreas Bircher Allergologische Poliklinik - Switzerland ASA/Beta-lactams (personnal protocol) and riphampicin (Int Arch Allergy Immunol 2006; 140:20-26) Pascal Demoly Hôpital Arnaud de Villeneuve - France ASA - >50 pts (1/10/20/50 mg every 30 min) CTZ - >100 pts (Demoly et al) Others (insulin, TB drugs, anti-HIV drugs) – some as CTZ

Task Force on Desensitization Drug Allergy Unit – Allergy and Clinical Immunology Division, Hospital São João and Oporto Faculty of Medicine, Portugal ASA 100mg (prophylaxis for CD)10 pts (modified protocol based in Stevenson et al) ASA 500 mg (AERD – nasal polyposis)5 pts (modified protocol based in Stevenson et al) Cotrimoxazole (HIV+ patients)>50 pts (modified protocol based in Demoly et al. J Allergy Clin Immunol Dec;102:1033-6) Penicillin (pregnant women, atb resistance)6 pts (based on Middleton’s Allergy: Principles and Practice 4th edition) Allopurinol (gout)3 pts (based in Allergy Jul;58(7):690) Levofloxacin (pts with bronchiectasis)1 pt (based on oral penicillin desensitization protocol) Carboplatin (optochiasmatic gliomas)3 pts (based in Lee et al Gynecol Oncol Nov;99(2):393-9)

Task Force on Desensitization Drug Allergy Unit – Allergy and Clinical Immunology Division, Hospital São João and Oporto Faculty of Medicine, Portugal Insulin2 pts ( based on Drug Allergy and Protocols for Management of Drug Allergies – 2nd Edition. Roy Patterson et al) Riphampicin (HIV+ and TB infection)3 pts (based on (Int Arch Allergy Immunol 2006; 140:20-26) Isoniazid (systemic TB)2 pts. Josefina Rodrigues et al, (The Internet Journal of Pharmacology Volum 3 Number1) L-asparaginase – E coli (Leukemia)4 pts (based on J Allergy Clin Immunol 1998;101: ) Anastrozole (Breast cancer)2 pts - Personnal protocol (EAACI 2007) Anti-thymocyte globulin (thymoglobulin) - leukemia 1 pt (based on J Allergy Clin Immunol 1998;101: ) - Failure Methylphenidate (ADHS)1 pt (based on J Child Adolesc Psychopharmacol. 2005;15:703-5) EAACI 2007 Sulfasalazin (IBD)4 pts (based on Ann Allergy Asthma Immunol. 1999;83:23-4

Task Force on Desensitization Proposal –Register desensitization protocols in EXCEL program Main disease Concomitant diseases Drug Initial dose Route of administration Interval Cumulative dose Continuous Intermittent Outcomes Protocol reference(s)